Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Aquyre Biosciences is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bertrand LecontedePoly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aquyre Biosciences
Developer of cellular level optical biopsies imaging systems designed to provide immediate biopsies results to avoid the delay of receiving a report. The companys systems provide cellular resolution imaging services, enabling researchers to conduct non-invasive and nondestructive optical biopsies using light to take optical biopsies beneath the surface of the tissue under analysis. CelTivity allows for tissue adequacy from a fresh and unprocessed biopsy. To scan and process a tissue sample takes as little as 2 minutes. The freshly excised sample can then be sent to pathology, along with the CelTivity data. The results allow clinicians intraprocedural identification and interpretation of different cell types such as cancer cells, immune cells, granuloma, and others to properly assess tissue samples for adequacy.

To learn more about Aquyre Biosciences, visit http://aquyre.com/

Contact:
Bertrand LecontedePoly, Chief Executive Officer
33 178 96 5000
https://www.linkedin.com/in/bertrand-le-conte-de-poly-ab5aa4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved